Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets

mAbs

Volumn 2, Issue 5, 2010, Pages 576-588

  Davda, Jasmine P ^a   Hansen, Ryan J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antigen; Ligand; Mechanism based; Monoclonal antibody; PK PD modeling

Indexed keywords

ANTIBODY; LIGAND; RECOMBINANT ANTIBODY;

ARTICLE; HUMAN; IN VIVO STUDY; PHARMACODYNAMICS; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPUTER SIMULATION; HUMANS; KINETICS; LIGANDS; MODELS, BIOLOGICAL; PROTEIN BINDING; TIME FACTORS;

EID: 77958583035     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.5.12833     Document Type: Article

References (22)

1. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548-58.
2. Benincosa LJ, Chow FS, Tobia LP, Kwok DC, Davis CB, Jusko WJ. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J Pharmacol Exp Ther 2000; 292:810-6.
3. Chow FS, Benincosa LJ, Sheth SB, Wilson D, Davis CB, Minthorn EA, et al. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther 2002; 71:235-45.
4. Jit M, Henderson B, Stevens M, Seymour RM. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome. Rheumatology (Oxford) 2005; 44:323-31. (Pubitemid 40361288)
5. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63:548-61. (Pubitemid 46632569)
6. Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther 2008; 326:555-62.
7. Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. Aaps J 2008; 10 425-30.
8. Furuya Y, Ozeki T, Takayanagi R, Yokoyama H, Okuyama K, Yamada Y. Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease. Drug Metab Pharmacokinet 2007; 22:20-5.
9. Meno-Tetang GM, Lowe PJ. On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin Pharmacol Toxicol 2005; 96:182-92.
10. Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS, et al. Efficacy, pharmacodynamics and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther 1997; 62:675-90. (Pubitemid 28068071)
11. Vugmeyster Y, Tian X, Szklut P, Kasaian M, Xu X. Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and Ascaris-challenged cynomolgus monkeys. Pharm Res 2009; 26:306-15.
12. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645-68.
13. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther 2005; 5:37-47.
14. Grimm HP. Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations. J Pharmacokinet Pharmacodyn 2009; 36:407-20.
15. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006; 72:1-10.
16. Gibiansky L, Gibiansky E. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 2009; 5:803-12.
17. Balthasar J, Fung HL. Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: studies using digoxin as a model drug. J Pharmacol Exp Ther 1994; 268:734-9.
18. Balthasar JP, Fung HL. Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments. J Pharm Sci 1996; 85:1035-43.
19. Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 2010;106:195-209
20. Betts A, Clark T, Yang J, Treadway J, Li M, Giovanelli M, et al. The application of target information and preclinical pharmacokinetic/ pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 2010; 333:2-13.
21. Lachmann H, Lowe P, Felix S, Rordorf C, Leslie K, Madhoo S, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206:1029-36.
22. Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 2003; 92:1206-15.